David P. Skoner

TL;DR: Use of once-daily grass AIT treatment effectively treats timothy grass (cross-reactive with Festucoideae grasses) pollen-induced ARC in North American children 5 years and older and might become an important addition to the North American ARC treatment armamentarium.

TL;DR: Standardized glycerinated short ragweed pollen extract administered sublingually at maintenance doses of 4.8 to 48 microg Amb a 1/d was safe and can induce favorable clinical and immunologic changes in ragweed-sensitive subjects, however, additional trials are needed to establish efficacy.

TL;DR: There is a need for a further review of the safety and tolerability of montelukast in children.

TL;DR: The differences in growth velocity, and the absence of drug-related cortisol effects, support the use of a total daily dose of 100 μg of MF-DPI in children aged 4–9 years with mild persistent asthma.

TL;DR: Small-particle inhaled corticosteroid inhalers were recently developed to treat asthma as part of the CFC to HFA propellant switch mandated by the Montreal Protocol and some studies suggest even higher systemic bioavailability and safety risk with smaller particles, depending on the molecule and the formulation.